“And what we mean by off-target is that they can direct the nucleases that perform the gene-editing step at other locations in the genome,” he told the Technology Networks audience back in 2024.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.